In summary, utilizing in vitro and in vivo data, this work demonstrates that piR-1742 promotes disease progression and leads to a dismal prognosis in patients with RCC by modulating the deubiquitination of key molecules, consequently activating downstream signaling cascades. Here, PIR is linked to renal cell adenocarcinoma.